Ideaya Biosciences Announced Clinical Program Updates For IDE397, Phase 2 MAT2A Inhibitor Targeting MTAP-Deletion Solid Tumors

Author: Benzinga Newsdesk | June 24, 2024 06:02am

• Targeting IDE397 Phase 2 monotherapy expansion dose clinical data update in over ~15 evaluable MTAP lung and bladder cancer patients in H2 2024, including RECIST 1.1 clinical efficacy waterfall, swim-lane plot, ctDNA molecular response analysis, AE profile, PK and pharmacodynamics
• Initiating IDE397 Phase 2 monotherapy expansion in MTAP bladder cancer, in addition to the earlier reported Phase 2 expansion in MTAP squamous lung cancer
• Activated over 35 clinical trial sites globally across the U.S., Canada, Europe, and Asia Pacific to enable potential rapid enrollment for the IDE397 Phase 2 clinical program

Posted In: IDYA